Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.45 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.45 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2035215 | 0.99 | NPSR1 (0.51) | NPSR1AKR1C3MAPTKCNJ6KCNJ3 | |
| SCHEMBL8010517 | 0.90 | NPSR1 (0.52) | NPSR1MAPTKCNJ6KCNJ3LTA4H | |
| SCHEMBL8009940 | 0.89 | ALDH1A1 (0.57) | NPSR1MAPTLTA4HMEN1KMT2A | |
| SCHEMBL8009953 | 0.87 | SMN1; SMN2 (0.47) | NPSR1MAPTALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL8008245 | 0.86 | NPSR1 (0.48) | NPSR1MAPTFAAHALDH1A1MAPK1 | |
| SCHEMBL8009905 | 0.85 | MAPT (0.54) | NPSR1MAPTKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL7999011 | 0.84 | MET (0.51) | NPSR1MAPTKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL8013247 | 0.84 | BRD4 (0.51) | NPSR1MAPTFAAHALDH1A1SMN1; SMN2 | |
| SCHEMBL8007265 | 0.83 | KDM4E (0.50) | MAPTFAAHALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL7998139 | 0.83 | TRPV1 (0.47) | NPSR1MAPTALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240103007-A1 | MASS SPECTROMETRY SAMPLE PROCESSING METHODS, CHROMATOGRAPHY DEVICES, AND DATA ANALYSIS TECHNIQUES FOR BIOMARKER ANALYSIS | PROTEAS BIOANALYTICS, INC. (US) | 2024-03-28 | — | — | US | claimed |
| EP-4264274-A1 | MASS SPECTROMETRY SAMPLE PROCESSING METHODS, CHROMATOGRAPHY DEVICES, AND DATA ANALYSIS TECHNIQUES FOR BIOMARKER ANALYSIS | Proteas Bioanalytics, Inc. (US) | 2023-10-25 | — | — | EP | claimed |
| US-20230087609-A1 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | UNIVERSITEIT MAASTRICHT (NL) | 2023-03-23 | — | — | US | claimed |
| US-20230083417-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | UNIVERSITEIT MAASTRICHT (NL) | 2023-03-16 | — | — | US | claimed |
| EP-4110396-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | Universiteit Maastricht (NL) | 2023-01-04 | — | — | EP | claimed |
| EP-4106741-A1 | USE OF A SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATOR OR OF A COMBINATION OF A SGC STIMULATOR AND AN SGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF SGC IS OXIDIZED OR WHEREIN SGC IS DEFICIENT IN HEME | Universiteit Maastricht (NL) | 2022-12-28 | — | — | EP | claimed |
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | claimed |
| WO-2022132834-A1 | MASS SPECTROMETRY SAMPLE PROCESSING METHODS, CHROMATOGRAPHY DEVICES, AND DATA ANALYSIS TECHNIQUES FOR BIOMARKER ANALYSIS | PROTEAS BIOANALYTICS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| CN-114144229-A | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | 梅约医学教育与研究基金会 | 2022-03-04 | — | — | CN | claimed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | claimed |
| US-20050181066-A1 | Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | US | claimed |
| EP-1501605-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA Pharma AG (DE) | 2005-02-02 | — | — | EP | claimed |
| WO-2003090870-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | claimed |
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3532063-B1 | COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION | PULMOKINE INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2008124505-A2 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS,INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20050181066-A1 | Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | US | disclosed |
| EP-1501605-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA Pharma AG (DE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003090870-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | PDE2A, PRKG1, GUCY1A2 | NPSR1 1857/4885AKR1C3 4422/4885MAPT 4558/4885 |
| US-20230087609-A1 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | GUCY1A1, GUCY1B1, GUCY1A2 | NPSR1 3795/4885AKR1C3 635/4885MAPT 4679/4885 |
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | PDE9A, PDE2A, GUCY1A2 | NPSR1 2001/4885AKR1C3 4147/4885MAPT 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.